AC Immune

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AC Immune and other ETFs, options, and stocks.

About ACIU

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.

CEO

Andrea Pfeifer

CEOAndrea Pfeifer

Employees

172

Employees172

Headquarters

Lausanne, Vaud

HeadquartersLausanne, Vaud

Founded

2003

Founded2003

Employees

172

Employees172

ACIU Key Statistics

Market cap

349.27M

Market cap349.27M

Price-Earnings ratio

-6.10

Price-Earnings ratio-6.10

Dividend yield

—

Dividend yield—

Average volume

426.74K

Average volume426.74K

High today

$3.78

High today$3.78

Low today

$3.46

Low today$3.46

Open price

$3.50

Open price$3.50

Volume

473.31K

Volume473.31K

52 Week high

$3.99

52 Week high$3.99

52 Week low

$1.43

52 Week low$1.43

ACIU News

Simply Wall St 4d

AC Immune Is Up 24.2% After Positive ACI-35.030 Trial Publication in Alzheimer's Disease

AC Immune SA recently announced the peer-reviewed publication of positive Phase 1b/2a trial results for its active immunotherapy ACI-35.030, in partnership with...

Simply Wall St 5d

AC Immune (NasdaqGM:ACIU): Exploring Valuation Following Promising Phase 1b/2a Alzheimer’s Data Publication

AC Immune (NasdaqGM:ACIU) just shared peer-reviewed data from its Phase 1b/2a trial of ACI-35.030, an active immunotherapy targeting Tau in early Alzheimer's, d...

People also own

Based on the portfolios of people who own ACIU. This list is generated using Robinhood data, and it’s not a recommendation.